Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective

Author(s): Grazyna Skuza

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 7 , 2012

Become EABM
Become Reviewer
Call for Editor


The σ receptors are regarded as unique binding sites, distinct from opiate and PCP receptors and implicated in higher brain function. They were classified into σl and σ2 subtypes, the former was cloned from rodent and human tissues while the latter has not yet been fully characterized. Although the precise mechanism of the functional response of σ receptors is still uncertain, it has been accepted that they can modulate a number of central neurotransmitter systems, including glutamate/NMDA, serotonergic, dopaminergic, noradrenergic routes, as well as some other signaling pathways (e.g. neurotrophin and growth factor signaling) which are seemingly important for the brain function. In accordance with their modulatory role, σ receptor ligands have been proposed to be useful in several therapeutic areas such as schizophrenia, depression and anxiety, amnesic and cognitive deficits, drugs of abuse. The present review summarizes the findings related to the pharmacological effects and potential activity of σ receptor ligands from behavioral models predictive of some neuropsychiatric disorders.

Keywords: σ1- and σ2-receptor ligands, behavioral effect, dopamine (DA) agonists, phencyclidine (PCP), prepuls inhibition (PPI), forced swim test (FST), olfactory bulbectomy (OB), anxiety, cocaine, learning and memory

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [863 - 874]
Pages: 12
DOI: 10.2174/138161212799436458
Price: $65

Article Metrics

PDF: 30